Strategic acquisitions transform Cerecor into a leading U.S. Pediatric Pharmaceutical Company
Company announces initiation of a clinical development program for CERC-301 in Neurogenic Orthostatic Hypotension
BALTIMORE, MD — (Marketwired) — 04/02/18 — Cerecor Inc. (NASDAQ: CERC) today announced financial results for the fourth quarter and full year 2017. Net Revenues for the year ended 2017 were $27.8 million. As of December 31, 2017, the Company had $43.1 million in total assets including cash and cash equivalents of $2.5 million, accounts receivable of $3.3 million, and escrowed receivable of $3.8 million. Total liabilities were $15.3 million and Total Stockholder’s equity was $27.9 million.